Genetic variations associated with pharmacoresistant epilepsy (Review)
- Authors:
- Published online on: February 24, 2020 https://doi.org/10.3892/mmr.2020.10999
- Pages: 1685-1701
-
Copyright: © Cárdenas‑Rodríguez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Epilepsy is one of the most common neurological diseases worldwide and is considered a major public health problem (1,2). The International League Against Epilepsy (ILAE) has established that the term ‘epilepsy’ refers to a disease of the brain that meets any of the following conditions: i) At least two non-induced seizures, or reflexes, that occur ≥24 h apart; ii) one non-induced seizure, or reflex, and a risk of further seizures similar to the general recurrence risk (≥60%) following two non-induced seizures that occur over the next 10 years; or iii) the diagnosis of an epilepsy syndrome (3,4). Epilepsy is considered to be resolved when an individual with epilepsy has remained seizure-free for 10 years and without antiepileptic drug treatment for ≥5 years (4).
For the most accurate study of epilepsy, the ILAE (5,6) has organized and classified seizures and several epilepsy types as focal, generalized and of unknown onset, based on certain characteristics, including seizure type, electroencephalography (EEG) features, imaging studies, age-related features and triggering factors, such as comorbidities and prognosis (6,7); this classification involved the work of epileptologists, neurophysiologists and epilepsy researchers (6).
A previous study demonstrated that epileptic seizures are associated with several mechanisms that involve the glutamate excitotoxicity process, microglial activation, mitochondrial dysfunction, degenerative processes, and the presence of reactive oxygen species and oxidative stress (8). In addition, it has previously been reported that certain regulatory processes are involved at the transcriptional level; for example, the nuclear transcription factor erythroid-derived 2-like 2 was revealed to serve a role in epileptic seizures (9,10). A recent study conducted by our group used microarray analysis in children with epilepsy to demonstrate that those with epilepsy overexpressed genes that were related to the transcriptional factor cAMP-response element binding protein (CREB) compared with normal children, in addition to significantly altered expression levels of genes involved in energy metabolism, redox balance and the immune response (11). The differential gene expression, particularly genes related to CREB, observed in children before and after the administration of valproic acid indicated that the activity of antiepileptic drugs (AED) is dependent on target genes. These data suggested a role for genetics in epilepsy development and highlighted the importance of studying the genetic mechanisms associated with drug resistance. This would provide an improved understanding of the impact of pharmacological treatment on epilepsy and in the patient's daily activities, of which both are influenced by: i) The patient's response to treatment; ii) the relationship between the number and type of seizures, and the modified transportation of proteins or their receptors due to the drug's activity and the presence of genetic variations; iii) the possible influence of the phenotypic characteristics of the patient in response to the treatment; iv) the impact of the presence of the genetic variants in the functionality of the transporting proteins and AED target proteins; v) the interference of the potential alterations in the target protein on the mechanism of action of the AED due to the presence of the variant; vi) the influence of the inflammatory and immunological response; vii) the predisposition to some of the different aspects of epilepsy, including refractoriness or decreased sensitivity to the AED effect; and viii) the result following the combination of several of these or other mechanisms (12–15). In accordance with the last point, the objective of the present review was to focus on describing the findings of genetic alterations involved in pharmacoresistant epilepsy.
Pharmacoresistant epilepsy
The term pharmacoresistant epilepsy refers to a type of epilepsy that does not respond to at least two AEDs, which were chosen and used in monotherapy or combination therapy (bi- or polytherapy) and fail to fully control seizures for an adequate period (16). In 2011, the ILAE proposed to standardize the definition of pharmacoresistant epilepsy as the presence of seizures in a period of 6 months, even under proper therapeutic regimens (either monotherapy or in combination) (16). Two studies performed in 2000 and 2012 reported that people with epilepsy (PWE) responded differently to AED treatment, since 47–49.5% of the patients required one AED to control the seizures, 13–13.3% required a second AED, and 3.7–4% needed a third AED, which was administered either alone or in combination (17,18). To summarize, Kwan and Brodie (17) observed that in a prospective study of 525 PWE (age, 9–93 years), 333 of them (63%) remained seizure-free during AED administration and seizures that did occur were more persistent in patients with symptomatic and cryptogenic epilepsy (40%) compared with those with idiopathic epilepsy (26%). Moreover, among 470 previously untreated patients, 222 of them (47%) became seizure-free during treatment with their first AED, 67 patients (14%) became seizure-free during treatment with a second or third AED and 12 patients (3%) were controlled with two AEDs administered together (17). Brodie et al (18) subsequently discovered that patients have differential responses to AEDs; out of 1,098 PWE (ages, 9–93 years) studied, 749 of them (68%) were seizure-free with AED monotherapy, but in 272 patients (25%), freedom from seizures was never attained. Moreover, <2% of patients became seizure-free with the use of up to six or seven AEDs (18). In addition to the above findings, epidemiological studies conducted among children and adults have discovered that 20–40% of PWE present with pharmacoresistant epilepsy (19–22), which negatively impacts their quality of life because it is also associated with increases in psychiatric comorbidities and the risk of premature death and social discrimination (23).
It is important to highlight that pharmacoresistant epilepsy may also cause serious socioeconomic problems. For instance, Argumosa and Herranz (24) evaluated the economic cost of controlled and uncontrolled epilepsy in Spain (participants were <14 years old) and reported that the mean annual cost of controlled epilepsy was $2,002.36 USD, whereas the cost of uncontrolled epilepsy was $5,348.50 USD; thus, uncontrolled epilepsy was 2.7 times more expensive compared with controlled epilepsy. Given the elevated costs of treatment, alternative therapeutic approaches, such as the ketogenic diet (25), high doses of steroids (26) and brain surgery (27) have all been implemented The ketogenic diet has proved beneficial in PWE in which pharmacological and/or surgical treatment is not effective; this diet is centered around a very high-fat and low-carbohydrate intake, reducing carbohydrates to <10% of used energy (90% of the total caloric intake comes from fat, 6% from protein and 4% from carbohydrates). These proportions trigger a systemic shift from glucose metabolism towards the metabolism of fatty acids, which yields ketone bodies that serve as the energy source to replace glucose in the brain (28). In patients with pharmacoresistant epilepsy, a ketogenic diet has been observed to improve the quality of life and decreases seizure frequency in ~30% of patients (25). In a significant number of patients with pharmacoresistant epilepsy, curative epilepsy surgery cannot be offered since there are multiple epileptogenic zones; for these patients, neurostimulation techniques, such as vagus nerve stimulation, deep brain stimulation and responsive neurostimulation, are viable treatment options that should be considered in every patient with this type of epilepsy that is unsuitable for surgery (27,29). These techniques provide palliative care, resulting in a 10–80% reduction in seizure occurrence (29). Furthermore, if all the aforementioned treatment approaches fail to control the seizures, cannabidiol (Epidiolex®) can be prescribed; this is a pharmaceutical product approved by the U.S. Food and Drug Administration that consists of 99% cannabidiol derived from cannabis (30,31). A previous study reported that out of 43 Mexican children with pharmacoresistant epilepsy, a decrease in the number of epileptic seizures were observed in 81.3% of patients and 20.9% patients displayed a reduction in the number of AEDs with the use of cannabidiol. Significant adverse effects related to appetite or sleep were only observed in 42% of patients following the use of cannabidiol (31).
Genetic variations associated with pharmacoresistant epilepsy
Previous studies have suggested that pharmacokinetic and pharmacodynamic mechanisms form the physiopathological basis of pharmacoresistant epilepsy (Table I) (22,32,33). Advances in genomic technologies have facilitated the genome-wide discovery of common and rare variants and have increased our understanding of genetics in epilepsy (34); however, the mechanisms underlying pharmacological resistance have not been fully elucidated (35). Some of the most important genes associated with the physiopathology of epilepsy were associated with the neuronal acetylcholine receptor, neuronal potassium channels (KCNs), voltage-dependent sodium channels (SCNs), calcium channels and γ-aminobutyric acid (GABA) receptors (32,36,37). Table II summarizes some of the genetic variants that occur in the main genes linked to epilepsy from recent studies.
In the particular case of pharmacoresistant epilepsy, the most frequently studied polymorphisms are those associated with multidrug resistance genes (MDR): ATP-binding cassette subfamily B member 1 (ABCB1 or MDR1) and ATP-binding cassette subfamily C member 2 (ABCC2 or MRP2); SCN α subunits 1, 2 and 3 (SCN1, SCN2 and SCN3); and metabolizers of endogenous and xenobiotic substances, cytochromes P450 families 2 and 3 (CYP2 and CYP3). Additional details related to the findings of these studies are found in Table III.
The role of genetic variants in the diagnosis and treatment of pharmacoresistant epilepsy
Currently, a patient's medical history and EEG results are used to diagnose the type of seizure, but they must be interpreted with caution so that diagnostic errors are not made; this suggests the use of complementary studies (38). Emerging genomic technologies, high-throughput screening and chip technologies have accelerated our understanding of the genetic makeup of epilepsy (34); for instance, the identification of mutations or polymorphisms in specific genes, such as those that encode ion channels, aforementioned, that are mainly expressed in brain neurons, specific neurotransmitter receptors and molecules that have functions in intercellular communication (39). For example, a study by Wang et al (40) investigated the genetic etiology of epilepsy in a cohort of 120 children with unexplained epilepsy using whole-exome sequencing (WES); it was found that the pathogenic variant c.1174G>A in the KCN subfamily D member 3 (KCND3) gene may be responsible for a broader phenotypic spectrum than was previously thought, including infantile epileptic encephalopathy. In addition, this study discovered that the glutamate receptor, ionotropic glutamate ionotropic receptor NMDA-type subunit 1 (GRIN1) and hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 (HCN1), were candidate gene variants (c.2530C>T and c.1138A>T for GRIN1 and HCN1, respectively) for the Dravet and Dravet-like phenotypes (40). In intractable epilepsy and other mental disabilities, WES identified de novo variants in the Bernardinelli-Seip congenital lipodystrophy 2 (BSCL2) gene in two patients (41), of which one of the variants (c.985C>T) has been observed in other populations of epilepsy and developmental regression, regressive autism spectrum disorder, motor stereotypies, lower limb hypertonia and frontal lobe syndrome (41). As it was discovered that BSCL2 serves a role in neuronal function, it was suggested to be a potential candidate gene for epileptogenesis (41).
In pyridoxine-dependent epilepsy (PDE), despite seizure control, ≥75% of patients experience intellectual disability and developmental delay, which emphasizes the importance of early diagnosis. Genetic tests are increasingly being used as first-level tests for epileptic encephalopathies, which aim to provide a general description of the mutations in the aldehyde dehydrogenase 7 family member A1 that causes PDE (42). Epilepsy with myoclonic-atonic seizures (EMAS) accounts for 1–2% of all childhood onset epilepsies (43). EMAS has been demonstrated to have an underlying genetic component and several genes have been associated with this disease, such as SCN1A, SCN2A, CHD2, STX1B, SLC2A1, SLC6A1, POLG1, NRXN1, PIGN, CSNK2A1, GABRG2 and GABRB3; however, the genetic basis for this disorder remains unknown and the diagnostic potential of genetic tests remains low. This could be explained by the lack of several of the genes that may be associated with EMAS in the most commonly ordered epilepsy panels, although some have recently been added (43–47). Furthermore, a study conducted by Ortega-Moreno et al (48) analyzed a multigenic panel of 87 PWE and developmental delay, including classified and unclassified epileptic encephalopathies, epileptic spasms, severe myoclonic epilepsy of infancy, Lennox-Gastaut and Landau-Kleffner syndromes; they found mutations in various genes, such as potassium voltage-gated channel subfamily Q member 2 (KCNQ2), syntaxin binding protein 1, UDP-N-acetylglucosaminyltransferase subunit, cyclin dependent kinase-like 5 (CDKL5), protocadherin 19, SCN1A, CHD2, SLC2A1, synaptic Ras GTPase activating protein 1, aristaless related homeobox, DNA polymerase gamma, catalytic subunit and GRIN1. Although a high proportion of these patients had unclassified epilepsies, the results supported the use of the multigene epilepsy panel because it offered rapid testing with a good diagnostic efficiency (48).
It is hypothesized that genetic variants may also contribute to the efficacy of drug treatments for epilepsy; for example, adverse or toxic reactions, teratogenic risk in pregnancy, as well as long-term outcomes have been observed among PWE (49–63). Consistent with the findings in numerous other disorders with complex genetic backgrounds, the associated genetic variants that have been successfully verified are limited. Nevertheless, it is likely that new techniques and improved research approaches will increase this number in the near future (49). In recent studies, the association between genetic polymorphisms, treatment responses in epilepsy and AEDs reactions (toxic, adverse or those related with its efficacy) have been investigated; it was reported that polymorphisms in the human leukocyte antigen (HLA) gene were associated with severe cutaneous adverse AED reactions (50), and polymorphisms in a number of other genes, including ABCB1, ABCC2, GABRA6, GABRG2, CYP2C9, CYP3A4, UDP-glucuronosyltransferase (UGT)1A1, UGT1A4, UGT1A6, UGT2B7, SCN2A and SCN1A, have been associated with the concentration, response and efficacy of some of the most commonly used AEDs in clinical practice, including carbamazepine, oxcarbazepine, phenytoin, lamotrigine and valproic acid (51–63). Esmaeilzadeh et al (50) reported an association between HLA polymorphisms and severe cutaneous adverse reactions (SCARs) induced by drugs; in this study, 61 patients with diverse SCARs were recruited, and it was found that the hypersensitivity to different AEDs, including phenytoin, carbamazepine, valproic acid, topiramate and lamotrigine, was associated with HLA-A gene polymorphisms. Berghuis et al (64) recruited 1,328 adult PWE who had received oxcarbazepine (n=1,031) and carbamazepine (n=297) and performed a genome-wide association study to demonstrate the association between genetic factors and sodium levels and AED metabolism. The authors did not observe significant associations between sodium levels and other clinical variables, but in relation to carbamazepine metabolism, they observed a significant association with the intronic rs2234922 polymorphism in the epoxide hydrolase 1 gene. Furthermore, the same authors reported in 2017 that carbamazepine and oxcarbazepine induced hyponatremia in those with epilepsy (65); in this study, 1,782 adult patients who carbamazepine (n=1,424) and oxcarbazepine (n=358) were recruited; using an electronic database designed for pharmacogenomics studies, it was found that sodium levels were significantly associated with serum levels of carbamazepine (P<0.001) and oxcarbazepine (P=0.001), whilst age, sex and the number of concomitantly used AEDs did not influence this association. Serum levels of carbamazepine [Odds Ratio (OR)=1.2; 95% CI=1.12–1.28; P<0.001] and oxcarbazepine (OR=1.06; 95% CI=1.02–1.1; P=0.001) were significantly associated with hyponatremia. The co-treatment and the sequential use of carbamazepine and oxcarbazepine were also related to severe hyponatremia (65). McCormack et al (66) recruited patients with maculopapular exanthema (MPE) associated with AED use (all aromatic AEDs: n=259 European and n=116 Han Chinese patients; carbamazepine: n=95 European and n=85 Han Chinese patients; lamotrigine: n=118 European and n=16 Han Chinese patients; phenytoin: n=52 European and n=22 Han Chinese patients) and 1,321 controls and performed a genome-wide association to analyze the association between AED use and MPE. It was found that within the European population, variations in HLA-A*31:01 were significantly associated with carbamazepine-induced MPE (OR=5.5; 95% CI=3–10; P=1.47×10−10). Regarding phenytoin use, a significant association was identified between the rs78239784 polymorphism and an intronic variant of the complement factor H-related 4 gene in the European population (OR=8.8; 95% CI=4–19; P=2.94×10−10) (66). Bai et al (67) observed that VPA induced obesity in PWE, as following the recruitment of 225 Chinese Han patients with epilepsy receiving VPA treatment, 19.6% were found to be obese. The authors also found genotypic associations of rs1194197 in the CD36 gene and rs10865710 in the peroxisome proliferator-activated receptor γ gene following weight gain. In another study conducted by Li et al (68), associations between the rs1137101 polymorphism in the leptin receptor (P<0.001), the rs1800497 polymorphism in the ankyrin repeat kinase domain-containing 1 (P=0.017) and the rs10789038 polymorphism in AMP protein kinase (P=0.02) with valproic acid-induced weight gain were observed in 212 PWE (68). Wang et al (69) discovered that some polymorphisms were associated with the adverse effects of valproic acid in Chinese PWE by direct sequencing; following the recruitment of 254 Chinese PWE that received valproic acid monotherapy, a correlation was identified between CYP2C9 and acyl-coenzyme A synthetase 2A (ACSM2A) gene polymorphisms with serum alanine aminotransferase and aspartate aminotransferase levels (P<0.03) indicating that these gene polymorphisms can be used to identify liver dysfunction (69).
The therapeutic effect of valproic acid among children with focal epilepsy (89 children) was also studied, and the results identified 66 single nucleotide polymorphisms (SNPs) that were involved in the metabolism and transport of valproic acid target receptors (54); however, among the children with focal seizures, the selected genetic polymorphisms were not significantly associated with the response to valproic acid. Nonetheless, three variants of GABRA6 (rs9313892, rs4921195 and rs424740) demonstrated the potential to be associated with the response to valproic acid (54). In addition, although polymorphisms in the SCN1A gene are thought to influence the efficacy of carbamazepine and phenytoin, Manna et al (70) found that the rs3812718 variant in SCN1A was not associated with the response to carbamazepine in patients with focal epilepsy. It has been reported that disorders related to changes in the KCNQ2 gene included both benign seizure disorders and early onset epileptic encephalopathies (EOEE), especially the latter, which includes patients who present refractory seizures following standard AED treatment and development delay (71–73). Kuersten et al (74) conducted a systematic review (52 studies including data from 217 patients), in which they analyzed AEDs in KCNQ2-related epilepsies; it was discovered that seizures associated with KCNs could be controlled upon treatment with carbamazepine, lamotrigine, oxcarbazepine, phenytoin, valproic acid, levetiracetam, topiramate, phenobarbital, piracetam, vigabatrin, clonazepam, diazepam and midazolam in patients with benign infantile or neonatal seizures (n=133 patients, including 74 who were seizure-free with monotherapy, 4 who were unsuccessfully treated with monotherapy, 11 who were seizure-free with polytherapy, 4 patients with no response to polytherapy or any treatmet and 40 showed seizure cessation spontaneously without AEDs). Moreover, the results also demonstrated that moderate control of seizures was achieved with the use of carbamazepine, oxcarbazepine, lamotrigine, lacosamide, phenytoin, phenobarbital, valproic acid, topiramate, levetiracetam, retigabine, zonisamide, sultiame, ethosuximide, acetazolamide, clonazepam, diazepam, clobazam, nitrazepam and midazolam in patients with EOEE (n=84, including 48 who were seizure-free with monotherapy, 12 that did not respond to monotherapy, 20 who were seizure-free following polytherapy and 4 patients exhibited seizure reduction without AED). Phenobarbital was the most common prescribed monotherapy in the majority of patients with benign seizures and EOEE (n=65 in benign seizures and n=35 in patients with EOEE); however, the use of sodium channel blockers, such as carbamazepine, lamotrigine, oxcarbazepine and phenytoin, led to seizure cessation in the majority of patients with benign seizures and EOEE (n=21 benign seizures and n=45 with EOEE). With regards to the genetics, 25.6 and 67.9% of patients with benign seizures and EOEE, respectively, were reported to have de novo mutations, including missense, frameshift, splice site, deletion and truncation mutations. However, sparse systemic data are available on the response of treatment in KCNQ2-related epilepsy in larger cohorts (74), which limit our ability to comment on the efficacy of personalized medicine approaches to treat the large number of newly discovered genetic channelopathies.
The effects of SNPs in three KCN genes, including KCNA1 (rs112561866, rs2227910 and rs7974459), KCNA2 (rs3887820) and KCNV2 (rs7029012, rs10967705 and rs10967728), and their association with the susceptibility to epilepsy and their ability to respond to AEDs (carbamazepine for partial epilepsy and valproic acid for generalized epilepsy) was analyzed in a pharmacogenetic cohort of 595 patients (75). The results suggested that KCNA1, KCNA2 and KCNV2 did not influence the susceptibility of the disease or the capacity to respond to drugs (75). Mutations in the SCN2A gene have also been associated with neonatal seizures and a wide number of epileptic syndromes (76,77). Recently, an association between rs17183814 in SCN2A and the function of oxcarbazepine was demonstrated in a cohort of 218 patients; the results indicated that the presence of the SNP was associated with higher oxcarbazepine maintenance doses in patients with lower body weights and lower oxcarbazepine maintenance doses in patients who were overweight (51). In a cohort of 201 patients treated with valproic acid, an association was reported between the presence of the SNP rs230416 in SCN2A and the response to the drug (78). Similarly, another study reported an association between the SNPs in SCN2A (rs2304016) and SCN3B (rs3851100) and AED responsiveness in a cohort of 595 patients who were treated with valproic acid for generalized epilepsy and carbamazepine for partial epilepsy; the results demonstrated that none of these SNPs were significantly associated with a response to the AED (79).
Previous studies have indicated that to improve the efficacy and safety of epilepsy treatments, it is necessary to conduct studies to identify the following: i) The possible influence of some of the phenotypic characteristics of patients in response to the treatments; ii) the relationship between the number and type of seizures; iii) the differences in drug transporting protein activity or receptor activity caused by the genetic variations; iii) the impact of the presence of a genetic variant on the functionality of transporting proteins and AED target proteins; iv) the effects of potential alterations in target proteins, owing to a genetic variant, in the mechanisms of action of an AED; and v) factors that may contribute to susceptibility and treatment outcomes.
Clinical implications of genetic variants in pharmacoresistant epilepsy
Personalized medicine is treatment of patients with therapy aimed at targeting their specific pathophysiology; however, currently, this has limited applications in clinical practice. Advancements in genetic epilepsy models and deep phenotyping techniques have the potential to revolutionize translational research, and will bring precision medicine to the forefront of clinical practice (80). In a needs assessment aimed at identifying the clinical challenges faced by physicians in diagnosing and treating children with epilepsy in Germany, Spain and the United States, it was reported that the main challenges were the application of guidelines in clinical practice, the identification of epilepsy and epileptic events, the integration of genetic tests into clinical practice, the integration of non-pharmacological treatments, the transition from pediatric to adult care and the participation and commitment of caregivers (80). These findings may support neuropediatricians who wish to specialize in epileptology to address these identified challenges based through precision medicine treatments (80). As we continue to gain an improved understanding of the true complexity underlying the physiopathology of genetic epilepsy and the identification of factors that are involved in phenotypic variations, it will be easier to address and understand genotype-phenotype correlations (81).
Previous studies on genetic epilepsy syndromes have provided insight into the mechanisms of epileptogenesis, and have suggested roles for a number of genes with different functions, including ion channel proteins and those associated with the synaptic vesicle cycle and energy metabolism (82). In addition, advanced genomic technologies, high-throughput sequencing and molecular diagnostics are increasingly improving our understanding of the genetic architecture in epilepsy, and molecular confirmation may influence the treatment prescribed for some monogenic epilepsies. Moreover, it is of crucial importance that genetic methods that are able to analyze all known genes at a reasonable cost be developed to discover novel therapeutic options and to implement individualized precision medical treatment regimens (82).
Conclusions and future perspectives
Genetic variations in the most common genes that encode channels, transporters, drug-metabolizing enzymes and receptors have been discussed in this Review with regards to their association with drug-resistant epilepsy, including: Sodium voltage-gated channels SCN1A, SCN2A, SCN3A, SCN8A and SCN1B); potassium voltage-gated channels (KCNA1, KCNA2, KCNB1, KCND7, KCNH5, KCNJ10, KCNQ2 and KCNT1); calcium voltage-gated channel subunit α1 H; ATP binding-cassette transporters (ABCB1, ABCC2, ABCC5 and ABCG2); mitochondrial transporter family members (SLC2A1, SLC6A1, SLC6A4, SLC6A11, SLC9A6, SLC25A22 and SLC35A2); drug-metabolizing enzymes (CYP2C1, CYP2C9, CYP2C19, CYP2D6, CYPP3A4 and CYP3A5); CDKL5; and GABA receptors (GABRA1 and GABBR1). These data may prove useful for future studies of drug resistance in epilepsy and may contribute to the generation of new diagnostic methods. In addition, these methods could subsequently support the development of improved treatment regimens, including novel pharmacological targets and pharmacological therapeutics. Overall, these findings may also improve the application of more personalized therapies, which would lead to the reduction in treatment and medical care costs, and increase the quality of life for patients and caregivers.
Acknowledgements
The technical assistance of Dr Perla Michelle Martínez of the Department of Public Health Sciences, Austin, University of Texas (TX, USA).
Funding
This work was supported by the E022 Program of the National Institute of Pediatrics (protocol no. 041/2018) and from CONACyT (Mexico) Doctoral Program of Medical, Dental and Health Sciences, Clinical Experimental Health Research, The National Autonomous University of Mexico (grant no. 706968) and the SNI-CONACYT Fellows (NC-R, LC-A, DO-C and SG-M).
Availability of data and materials
Not applicable.
Authors' contributions
LCA, DLPL, SGM and IIM wrote and revised the manuscript; DOC critically revised and corrected the manuscript; and NCR conceived the idea for the review, collected and interpreted the studies included, reviewed the manuscript and contributed significantly to the writing the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Glossary
Abbreviations
Abbreviations:
PWE |
people with epilepsy |
EMAS |
epilepsy with myoclonic-atonic seizures |
EOEE |
early onset epileptic encephalopathies |
References
Camfield P and Camfield C: Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 17:117–123. 2015.PubMed/NCBI | |
Carod-Artal FJ and Vázquez-Cabrera CB: An anthropological study about epilepsy in native tribes from Central and South America. Epilepsia. 48:886–893. 2007. View Article : Google Scholar : PubMed/NCBI | |
López González FJ, Rodríguez Osorio X, Gil-Nagel Rein A, Carreño Martínez M, Serratosa Fernández J, Villanueva Haba V, Donaire Pedraza AJ and Mercadé Cerdá JM: Drug-resistant epilepsy: Definition and treatment alternatives. Neurologia. 30:439–446. 2015.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI | |
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, et al: ILAE official report: A practical clinical definition of epilepsy. Epilepsia. 55:475–482. 2014. View Article : Google Scholar : PubMed/NCBI | |
Golyala A and Kwan P: Drug development for refractory epilepsy: The past 25 years and beyond. Seizure. 44:147–156. 2017. View Article : Google Scholar : PubMed/NCBI | |
Falco-Walter JJ, Scheffer IE and Fisher RS: The new definition and classification of seizures and epilepsy. Epilepsy Res. 139:73–79. 2018. View Article : Google Scholar : PubMed/NCBI | |
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, et al: ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia. 58:512–521. 2017. View Article : Google Scholar : PubMed/NCBI | |
Waldbaum S and Patel M: Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 88:23–45. 2010. View Article : Google Scholar : PubMed/NCBI | |
Carmona-Aparicio L, Pérez-Cruz C, Zavala-Tecuapetla C, Granados-Rojas L, Rivera-Espinosa L, Montesinos-Correa H, Hernández-Damián J, Pedraza-Chaverri J, Sampieri A III, Coballase-Urrutia E, et al: Overview of Nrf2 as therapeutic target in epilepsy. Int J Mol Sci. 16:18348–18367. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cardenas-Rodriguez N, Coballase-Urrutia E, Pérez-Cruz C, Montesinos-Correa H, Rivera-Espinosa L, Sampieri A III and Carmona-Aparicio L: Relevance of the glutathione system in temporal lobe epilepsy: Evidence in human and experimental models. Oxid Med Cell Longev. 2014:7592932014. View Article : Google Scholar : PubMed/NCBI | |
Floriano-Sánchez E, Brindis F, Ortega-Cuellar D, Ignacio-Mejia I, Moreno-Arriola E, Romero-Morelos P, Ceballos-Vasquez E, Cordova-Espinoza MG, Arregoitia-Sarabia CK, Sandoval- Pacheco R, et al: Differential gene expression profile induced by valproic acid (VPA) in pediatric epileptic patients. Genes (Basel). 9(pii): E3282018. View Article : Google Scholar : PubMed/NCBI | |
Köhling R: Voltage-gated sodium channels in epilepsy. Epilepsia. 43:1278–1295. 2002. View Article : Google Scholar : PubMed/NCBI | |
Tan NC, Mulley JC and Berkovic SF: Genetic association studies in epilepsy: ‘The truth is out there’. Epilepsia. 45:1429–1442. 2004. View Article : Google Scholar : PubMed/NCBI | |
Semah F and Ryvlin P: Can we predict refractory epilepsy at the time of diagnosis? Epileptic Disord. 7 (Suppl 1):S10–S13. 2005.PubMed/NCBI | |
Fishman MC and Porter JA: Pharmaceuticals: A new grammar for drug discovery. Nature. 437:491–493. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S and French J: Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 51:1069–1077. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kwan P and Brodie MJ: Early identification of refractory epilepsy. N Engl J Med. 342:314–319. 2000. View Article : Google Scholar : PubMed/NCBI | |
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD and Kwan P: Patterns of treatment response in newly diagnosed epilepsy. Neurology. 78:1548–1554. 2012. View Article : Google Scholar : PubMed/NCBI | |
Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P and Crespel A: The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia. 49:1230–1238. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW and Newton CR: Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia. 51:883–890. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zavala-Tecuapetla C, Sampieri A III, Calderón-Guzmán D and Carmona-Aparicio L: Principales mecanismos de acción farmacológica en las crisis epilépticas díficiles de estabilizar. Acta Pediátr México. 32:125–127. 2011. | |
Espinosa-Jovel CA and Sobrino-Mejia FE: Drug resistant epilepsy. Clinical and neurobiological concepts. Rev Neurol. 61:159–166. 2015.(In Spanish). PubMed/NCBI | |
Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM, et al: Determinants of health-related quality of life in pharmacoresistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 52:2181–2191. 2011. View Article : Google Scholar : PubMed/NCBI | |
Argumosa A and Herranz J: La repercusión económica de las enfermedades crónicas: El coste de la epilepsia infantil en el año 2000. Bol Pediatr. 41:23–29. 2001. | |
Martin K, Jackson CF, Levy RG and Cooper PN: Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2:CD0019032016.PubMed/NCBI | |
Chudomelova L, Scantlebury MH, Raffo E, Coppola A, Betancourth D and Galanopoulou AS: Modeling new therapies for infantile spasms. Epilepsia. 51 (Suppl 3):S27–S33. 2010. View Article : Google Scholar | |
Baumgartner C, Koren JP, Britto-Arias M, Zoche L and Pirker S: Presurgical epilepsy evaluation and epilepsy surgery. F1000Res. 8(pii): F1000 Faculty Rev-1818. 2019.PubMed/NCBI | |
Ułamek-Kozioł M, Czuczwar SJ, Januszewski S and Pluta R: Ketogenic diet and epilepsy. Nutrients. 11(pii): E25102019. View Article : Google Scholar : PubMed/NCBI | |
Boon P, De Cock E, Mertens A and Trinka E: Neurostimulation for drug-resistant epilepsy: A systematic review of clinical evidence for efficacy, safety, contraindications and predictors for response. Curr Opin Neurol. 31:198–210. 2018. View Article : Google Scholar : PubMed/NCBI | |
García-Contreras F, Constantino-Casas P, Castro-Ríos A, Nevárez-Sida A, Estrada Correa Gdel C, Carlos Rivera F, Guzmán-Caniupan J, Torres-Arreola Ldel P, Contreras- Hernández I, Mould-Quevedo J and Garduño-Espinosa J: Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res. 37:376–383. 2006. View Article : Google Scholar : PubMed/NCBI | |
Aguirre-Velázquez CG: Report from a survey of parents regarding the use of cannabidiol (Medicinal cannabis) in Mexican children with refractory epilepsy. Neurol Res Int. 2017:29857292017. View Article : Google Scholar : PubMed/NCBI | |
Younus I and Reddy DS: A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol. 11:27–45. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tang F, Hartz AMS and Bauer B: Drug-resistant epilepsy: Multiple hypotheses, few answers. Front Neurol. 8:3012017. View Article : Google Scholar : PubMed/NCBI | |
Myers CT and Mefford HC: Advancing epilepsy genetics in the genomic era. Genome Med. 7:912015. View Article : Google Scholar : PubMed/NCBI | |
Depondt C: The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 10:57–65. 2006. View Article : Google Scholar : PubMed/NCBI | |
Mulley JC and Dibbens LM: Genetic variations and associated pathophysiology in the management of epilepsy. Appl Clin Genet. 4:113–125. 2011.PubMed/NCBI | |
Noebels J: Pathway-driven discovery of epilepsy genes. Nat Neurosci. 18:344–350. 2015. View Article : Google Scholar : PubMed/NCBI | |
Devinsky O: Patients with refractory seizures. N Engl J Med. 340:1565–1570. 1999. View Article : Google Scholar : PubMed/NCBI | |
Pal DK and Greenberg DA: Evaluating genetic heterogeneity in complex disorders. Hum Hered. 53:216–226. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Wen Y, Zhang Q, Yu S, Chen Y, Wu X, Zhang Y and Bao X: Gene mutational analysis in a cohort of Chinese children with unexplained epilepsy: Identification of a new KCND3 phenotype and novel genes causing Dravet syndrome. Seizure. 66:26–30. 2019. View Article : Google Scholar : PubMed/NCBI | |
Fernández-Marmiesse A, Sánchez-Iglesias S, Darling A, O'Callaghan MM, Tonda R, Jou C and Araújo-Vilar D: A de novo heterozygous missense BSCL2 variant in 2 siblings with intractable developmental and epileptic encephalopathy. Seizure. 71:161–165. 2019. View Article : Google Scholar : PubMed/NCBI | |
Coughlin CR II, Swanson MA, Spector E, Meeks NJL, Kronquist KE, Aslamy M, Wempe MF, van Karnebeek CDM, Gospe SM Jr, Aziz VG, et al: The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy. J Inherit Metab Dis. 42:353–361. 2019. View Article : Google Scholar : PubMed/NCBI | |
Angione K, Eschbach K, Smith G, Joshi C and Demarest S: Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures. Epilepsy Res. 150:70–77. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, Lesca G, Ville D, Milh M, Villard L, et al: Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 140:1316–1336. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kang JQ and Macdonald RL: Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to dravet syndrome. JAMA Neurol. 73:1009–1016. 2016. View Article : Google Scholar : PubMed/NCBI | |
Møller RS, Wuttke TV, Helbig I, Marini C, Johannesen KM, Brilstra EH, Vaher U, Borggraefe I, Talvik I, Talvik T, et al: Mutations in GABRB3: From febrile seizures to epileptic encephalopathies. Neurology. 88:483–492. 2017. View Article : Google Scholar : PubMed/NCBI | |
Johannesen KM, Gardella E, Linnankivi T, Courage C, de Saint Martin A, Lehesjoki AE, Mignot C, Afenjar A, Lesca G, Abi-Warde MT, et al: Defining the phenotypic spectrum of SLC6A1 mutations. Epilepsia. 59:389–402. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ortega-Moreno L, Giráldez BG, Soto-Insuga V, Losada-Del Pozo R, Rodrigo-Moreno M, Alarcón-Morcillo C, Sánchez- Martín G, Díaz-Gómez E, Guerrero-López R, Serratosa JM, et al: Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. PLoS One. 12:e01889782017. View Article : Google Scholar : PubMed/NCBI | |
Steinlein OK: Gene polymorphisms and their role in epilepsy treatment and prognosis. Naunyn Schmiedebergs Arch Pharmacol. 382:109–118. 2010. View Article : Google Scholar : PubMed/NCBI | |
Esmaeilzadeh H, Farjadian S, Alyasin S, Nemati H, Nabavizadeh H and Esmaeilzadeh E: Epidemiology of severe cutaneous adverse drug reaction and its HLA association among pediatrics. Iran J Pharm Res. 18:506–522. 2019.PubMed/NCBI | |
Yang X, Yan Y, Fang S, Zeng S, Ma H, Qian L, Chen X, Wei J, Gong Z and Xu Z: Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Medicine (Baltimore). 98:e149082019. View Article : Google Scholar : PubMed/NCBI | |
Huang J, Qian Z, Chen H, Huang Q, Huang L, Liu G and Tang X: Association of single nucleotide polymorphisms of SCN1A gene with therapeutic effect of carbamazepine among ethnic Zhuang Chinese patients with epilepsy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 36:271–274. 2019.(In Chinese). PubMed/NCBI | |
Shi L, Zhu M, Li H, Wen Z, Chen X, Luo J, Lin C and Zhang Z: SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. Eur J Clin Pharmacol. 75:655–663. 2019. View Article : Google Scholar : PubMed/NCBI | |
Feng W, Mei S, Han J, Zhu L, Yu Y, Gao B, Wu Y, Li J, Zhao Z and Fang F: Lack of association between valproic acid response and polymorphisms of its metabolism, transport, and receptor genes in children with focal seizures. Neurol Sci. 40:523–528. 2019. View Article : Google Scholar : PubMed/NCBI | |
Suzuki T, Mihara K, Nagai G, Kagawa S, Nakamura A, Nemoto K and Kondo T: Relationship between UGT1A4 and UGT2B7 polymorphisms and the steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy. Ther Drug Monit. 41:86–90. 2019. View Article : Google Scholar : PubMed/NCBI | |
Li Z and Wang Y: Relationship between UGT1A4 142T>G polymorphism and serum concentration of lamotrigine in Chinese epileptic patients: A meta-analysis. Zhonghua Yi Xue Za Zhi. 98:3365–3370. 2018.(In Chinese). PubMed/NCBI | |
Gailite L, Rots D, Pukite I, Cernevska G and Kreile M: Case report: Multiple UGT1A1 gene variants in a patient with Crigler-Najjar syndrome. BMC Pediatr. 18:3172018. View Article : Google Scholar : PubMed/NCBI | |
Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z and Fang F: Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures. Seizure. 58:96–100. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu L, Zhao L, Wang Q, Qiu F, Wu X and Ma Y: Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7-161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol. 71:1341–1347. 2015. View Article : Google Scholar : PubMed/NCBI | |
Sun YX, Zhuo WY, Lin H, Peng ZK, Wang HM, Huang HW, Luo YH and Tang FQ: The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res. 114:78–80. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kousar S, Wafai ZA, Wani MA, Jan TR and Andrabi KI: Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: Validatory pharmacogenomic approach to pharmacovigilance. Int J Clin Pharmacol Ther. 53:504–516. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhu X, Yun W, Sun X, Qiu F, Zhao L and Guo Y: Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 15:1867–1879. 2014. View Article : Google Scholar : PubMed/NCBI | |
Reimers A, Sjursen W, Helde G and Brodtkorb E: Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur J Drug Metab Pharmacokinet. 41:149–155. 2016. View Article : Google Scholar : PubMed/NCBI | |
Berghuis B, Stapleton C, Sonsma ACM, Hulst J, de Haan GJ, Lindhout D, Demurtas R, EpiPGX Consortium, Krause R, Depondt C, et al: A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open. 4:102–109. 2019. View Article : Google Scholar : PubMed/NCBI | |
Berghuis B, van der Palen J, de Haan GJ, Lindhout D, Koeleman BPC and Sander JW; EpiPGX Consortium, : Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 58:1227–1233. 2017. View Article : Google Scholar : PubMed/NCBI | |
McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, et al: Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 90:e332–e341. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bai X, Xu C, Wen D, Chen Y, Li H, Wang X, Zhou L, Huang M and Jin J: Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients. Psychopharmacology (Berl). 235:2665–2673. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li H, Wang X, Zhou Y, Ni G, Su Q, Chen Z, Chen Z, Li J, Chen X, Hou X, et al: Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. Int J Neuropsychopharmacol. 18:pyv0212015. View Article : Google Scholar : PubMed/NCBI | |
Wang C, Wang P, Yang LP, Pan J, Yang X and Ma HY: Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy Res. 132:64–69. 2017. View Article : Google Scholar : PubMed/NCBI | |
Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, et al: A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 52:e40–e44. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kothur K, Holman K, Farnsworth E, Ho G, Lorentzos M, Troedson C, Gupta S, Webster R, Procopis PG, Menezes MP, et al: Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy. Seizure. 59:132–140. 2018. View Article : Google Scholar : PubMed/NCBI | |
Fang ZX, Zhang M, Xie LL, Jiang L, Hong SQ, Li XJ, Hu Y and Chen J: KCNQ2 related early-onset epileptic encephalopathies in Chinese children. J Neurol. 266:2224–2232. 2019. View Article : Google Scholar : PubMed/NCBI | |
Goto A, Ishii A, Shibata M, Ihara Y, Cooper EC and Hirose S: Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy. Epilepsia. 60:1870–1880. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kuersten M, Tacke M, Gerstl L, Hoelz H, Stülpnagel CV and Borggraefe I: Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet. 63:1036282020. View Article : Google Scholar : PubMed/NCBI | |
Al-Eitan LN, Al-Dalalah IM, Elshammari AK, Khreisat WH and Almasri AY: The impact of potassium channel gene polymorphisms on antiepileptic drug responsiveness in Arab patients with epilepsy. J Pers Med. 8(pii): E372018. View Article : Google Scholar : PubMed/NCBI | |
Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, Webster R, Clark D, Freeman JL, Calvert S, et al: SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology. 85:958–966. 2015. View Article : Google Scholar : PubMed/NCBI | |
Turkdogan D, Thomas G and Demirel B: Ketogenic diet as a successful early treatment modality for SCN2A mutation. Brain Dev. 41:389–391. 2019. View Article : Google Scholar : PubMed/NCBI | |
Li X, Zhang J, Wu X, Yan H, Zhang Y, He RH, Tang YJ, He YJ, Tan D, Mao XY, et al: Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics. 17:2007–2014. 2016. View Article : Google Scholar : PubMed/NCBI | |
Al-Eitan LN, Al-Dalalah IM and Aljamal HA: Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility. Saudi Pharm J. 27:731–737. 2019. View Article : Google Scholar : PubMed/NCBI | |
Demarest ST and Brooks-Kayal A: From molecules to medicines: The dawn of targeted therapies for genetic epilepsies. Nat Rev Neurol. 14:735–745. 2018. View Article : Google Scholar : PubMed/NCBI | |
Murray S, Labbé S, Kothare S, Málaga I, Kluger G, Ogden P, Lazure P and Arzimanoglou A: Identifying the educational needs of physicians in pediatric epilepsy in order to improve care: Results from a needs assessment in Germany, Spain, and the United States. Epileptic Disord. 20:239–256. 2018.PubMed/NCBI | |
Striano P, Vari MS, Mazzocchetti C, Verrotti A and Zara F: Management of genetic epilepsies: From empirical treatment to precision medicine. Pharmacol Res. 107:426–429. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sánchez Alvarez JC, Serrano Castro PJ and Serratosa Fernández JM: Clinical implications of mechanisms of resistance to antiepileptic drugs. Neurologist. 13 (Suppl 1):S38–S46. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, Montesinos-Correa H, Bandala C, Carmona-Aparicio L and Coballase-Urrutia E: Role of oxidative stress in refractory epilepsy: Evidence in patients and experimental models. Int J Mol Sci. 14:1455–1476. 2013. View Article : Google Scholar : PubMed/NCBI | |
Trivisano M, Terracciano A, Milano T, Cappelletti S, Pietrafusa N, Bertini ES, Vigevano F and Specchio N: Mutation of CHRNA2 in a family with benign familial infantile seizures: Potential role of nicotinic acetylcholine receptor in various phenotypes of epilepsy. Epilepsia. 56:e53–e57. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang MY, Liu XZ, Wang J and Wu LW: A novel mutation of the nicotinic acetylcholine receptor gene CHRNA4 in a Chinese patient with non-familial nocturnal frontal lobe epilepsy. Epilepsy Res. 108:1927–1931. 2014. View Article : Google Scholar : PubMed/NCBI | |
Villa C, Colombo G, Meneghini S, Gotti C, Moretti M, Ferini-Strambi L, Chisci E, Giovannoni R, Becchetti A and Combi R: CHRNA2 and nocturnal frontal lobe epilepsy: Identification and characterization of a novel loss of function mutation. Front Mol Neurosci. 12:172019. View Article : Google Scholar : PubMed/NCBI | |
Goldberg-Stern H, Kaufmann R, Kivity S, Afawi Z and Heron SE: Novel mutation in KCNQ2 causing benign familial neonatal seizures. Pediatr Neurol. 41:367–370. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen DY, Chowdhury S, Farnaes L, Friedman JR, Honold J, Dimmock DP and Gold OBOTRIJJ: Rapid diagnosis of KCNQ2-associated early infantile epileptic encephalopathy improved outcome. Pediatr Neurol. 86:69–70. 2018. View Article : Google Scholar : PubMed/NCBI | |
Allen NM, Mannion M, Conroy J, Lynch SA, Shahwan A, Lynch B and King MD: The variable phenotypes of KCNQ-related epilepsy. Epilepsia. 55:e99–e105. 2014. View Article : Google Scholar : PubMed/NCBI | |
Piro E, Nardello R, Gennaro E, Fontana A, Taglialatela M, Donato Mangano G, Corsello G and Mangano S: A novel mutation in KCNQ3-related benign familial neonatal epilepsy: Electroclinical features and neurodevelopmental outcome. Epileptic Disord. 21:87–91. 2019.PubMed/NCBI | |
Miceli F, Striano P, Soldovieri MV, Fontana A, Nardello R, Robbiano A, Bellini G, Elia M, Zara F, Taglialatela M and Mangano S: A novel KCNQ3 mutation in familial epilepsy with focal seizures and intellectual disability. Epilepsia. 56:e15–e20. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lehman A, Thouta S, Mancini GMS, Naidu S, van Slegtenhorst M, McWalter K, Person R, Mwenifumbo J, Salvarinova R; CAUSES Study, ; et al: Loss-of-function and gain-of-function mutations in KCNQ5 cause intellectual disability or epileptic encephalopathy. Am J Hum Genet. 101:65–74. 2017. View Article : Google Scholar : PubMed/NCBI | |
Krepischi AC, Knijnenburg J, Bertola DR, Kim CA, Pearson PL, Bijlsma E, Szuhai K, Kok F, Vianna-Morgante AM and Rosenberg C: Two distinct regions in 2q24.2-q24.3 associated with idiopathic epilepsy. Epilepsia. 51:2457–2460. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liang JS, Lin LJ, Yang MT, Wang JS and Lu JF: The therapeutic implication of a novel SCN2A mutation associated early-onset epileptic encephalopathy with Rett-like features. Brain Dev. 39:877–881. 2017. View Article : Google Scholar : PubMed/NCBI | |
Davidsson J, Collin A, Olsson ME, Lundgren J and Soller M: Deletion of the SCN gene cluster on 2q24.4 is associated with severe epilepsy: An array-based genotype-phenotype correlation and a comprehensive review of previously published cases. Epilepsy Res. 81:69–79. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zaman T, Helbig I, Bozovic IB, DeBrosse SD, Bergqvist AC, Wallis K, Medne L, Maver A, Peterlin B, Helbig KL, et al: Mutations in SCN3A cause early infantile epileptic encephalopathy. Ann Neurol. 83:703–717. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yang Y, Zhang YH, Chen JY, Zhang J, Yang XL, Chen Y, Yang ZX and Wu XR: Clinical features of epilepsies associated with GABRB2 variants. Zhonghua Er Ke Za Zhi. 57:532–537. 2019.(In Chinese). PubMed/NCBI | |
Butler KM, Moody OA, Schuler E, Coryell J, Alexander JJ, Jenkins A and Escayg A: De novo variants in GABRA2 and GABRA5 alter receptor function and contribute to early-onset epilepsy. Brain. 141:2392–2405. 2018. View Article : Google Scholar : PubMed/NCBI | |
Orenstein N, Goldberg-Stern H, Straussberg R, Bazak L, Hubshman MW, Kropach N, Gilad O, Scheuerman O, Dory Y, Kraus D, et al: A de novo GABRA2 missense mutation in severe early-onset epileptic encephalopathy with a choreiform movement disorder. Eur J Paediatr Neurol. 22:516–524. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Lian Y and Xie N: Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report. Medicine (Baltimore). 96:e92732017. View Article : Google Scholar : PubMed/NCBI | |
Hernandez CC, Zhang Y, Hu N, Shen D, Shen W, Liu X, Kong W, Jiang Y and Macdonald RL: GABA a receptor coupling junction and pore GABRB3 mutations are linked to early-onset epileptic encephalopathy. Sci Rep. 7:159032017. View Article : Google Scholar : PubMed/NCBI | |
Farnaes L, Nahas SA, Chowdhury S, Nelson J, Batalov S, Dimmock DM and Kingsmore SF; RCIGM Investigators, : Rapid whole-genome sequencing identifies a novel GABRA1 variant associated with West syndrome. Cold Spring Harb Mol Case Stud. 3(pii): a0017762017. View Article : Google Scholar : PubMed/NCBI | |
Iqbal MJ, Wasim M, Rashid U, Zeeshan N, Ali R, Nayyab S, Habib S, Manzoor B and Zahid N: Mutational screening of GABRG2 gene in Pakistani population of Punjab with generalized tonic clonic seizures and children with childhood absence epilepsy. J Chin Med Assoc. 81:665–669. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bhat MA, Guru SA, Mir R, Waza AA, Zuberi M, Sumi MP, Bodeliwala S, Puri V and Saxena A: Association of GABAA receptor gene with epilepsy syndromes. J Mol Neurosci. 65:141–153. 2018. View Article : Google Scholar : PubMed/NCBI | |
Le SV, Le PHT, Le TKV, Huynh TTK and Do TTH: A mutation in GABRB3 associated with Dravet syndrome. Am J Med Genet A. 173:2126–2131. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ishii A, Kang JQ, Schornak CC, Hernandez CC, Shen W, Watkins JC, Macdonald RL and Hirose S: A de novo missense mutation of GABRB2 causes early myoclonic encephalopathy. J Med Genet. 54:202–211. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yoo Y, Jung J, Lee YN, Lee Y, Cho H, Na E, Hong J, Kim E, Lee JS, Lee JS, et al: GABBR2 mutations determine phenotype in rett syndrome and epileptic encephalopathy. Ann Neurol. 82:466–478. 2017. View Article : Google Scholar : PubMed/NCBI | |
Epi4K Consortium: De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet. 99:287–298. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Tong L, Song S, Niu Y, Li J, Wu X, Zhang J, Zai CC, Luo F, Wu J, et al: Novel and de novo mutations in pediatric refractory epilepsy. Mol Brain. 11:482018. View Article : Google Scholar : PubMed/NCBI | |
Hayashida T, Saito Y, Ishii A, Yamada H, Itakura A, Minato T, Fukuyama T, Maegaki Y and Hirose S: CACNA1A-related early-onset encephalopathy with myoclonic epilepsy: A case report. Brain Dev. 40:130–133. 2018. View Article : Google Scholar : PubMed/NCBI | |
Byers HM, Beatty CW, Hahn SH and Gospe SM Jr: Dramatic response after lamotrigine in a patient with epileptic encephalopathy and a de novo CACNA1A variant. Pediatr Neurol. 60:79–82. 2016. View Article : Google Scholar : PubMed/NCBI | |
Epperson MV, Haws ME, Standridge SM and Gilbert DL: An atypical rett syndrome phenotype due to a novel missense mutation in CACNA1A. J Child Neurol. 33:286–289. 2018. View Article : Google Scholar : PubMed/NCBI | |
Du X, Chen Y, Zhao Y, Luo W, Cen Z and Hao W: Dramatic response to pyridoxine in a girl with absence epilepsy with ataxia caused by a de novo CACNA1A mutation. Seizure. 45:189–191. 2017. View Article : Google Scholar : PubMed/NCBI | |
Heron SE, Khosravani H, Varela D, Bladen C, Williams TC, Newman MR, Scheffer IE, Berkovic SF, Mulley JC and Zamponi GW: Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol. 62:560–568. 2007. View Article : Google Scholar : PubMed/NCBI | |
Yoshida M, Nakashima M, Okanishi T, Kanai S, Fujimoto A, Itomi K, Morimoto M, Saitsu H, Kato M, Matsumoto N and Chiyonobu T: Identification of novel BCL11A variants in patients with epileptic encephalopathy: Expanding the phenotypic spectrum. Clin Genet. 93:368–373. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kurian M, Korff CM, Ranza E, Bernasconi A, Lübbig A, Nangia S, Ramelli GP, Wohlrab G, Nordli DR and Bast T: Focal cortical malformations in children with early infantile epilepsy and PCDH19 mutations: Case report. Dev Med Child Neurol. 60:100–105. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ko A, Youn SE, Kim SH, Lee JS, Kim S, Choi JR, Kim HD, Lee ST and Kang HC: Targeted gene panel and genotype- phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res. 141:48–55. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wang ZJ, Chen J, Chen HL, Zhang LY, Xu D and Jiang WT: Association between SCN1A polymorphism rs3812718 and valproic acid resistance in epilepsy children: A case-control study and meta-analysis. Biosci Rep. 38(pii): BSR201816542018. View Article : Google Scholar : PubMed/NCBI | |
Margari L, Legrottaglie AR, Vincenti A, Coppola G, Operto FF, Buttiglione M, Cassano A, Bartolomeo N and Mariggio MA: Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients. Seizure. 55:30–35. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ajmi M, Boujaafar S, Zouari N, Amor D, Nasr A, Rejeb NB, Amor SB, Omezzine A, Benammou S and Bouslama A: Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population. Int J Neurosci. 128:705–714. 2018. View Article : Google Scholar : PubMed/NCBI | |
Abou El Ella SS, Tawfik MA, Abo El Fotoh WMM and Soliman OAM: The genetic variant ‘C588T’ of GABARG2 is linked to childhood idiopathic generalized epilepsy and resistance to antiepileptic drugs. Seizure. 60:39–43. 2018. View Article : Google Scholar : PubMed/NCBI | |
Skalski D, Wendorff J, Romanowicz H, Rysz A, Marchel A, Stasiołek M and Smolarz B: Associations between MDR1 C3435T polymorphism and drug-resistant epilepsy in the Polish population. Acta Neurol Belg. 117:153–158. 2017. View Article : Google Scholar : PubMed/NCBI | |
López-Garcia MA, Feria-Romero IA, Serrano H, Rayo-Mares D, Fagiolino P, Vázquez M, Escamilla-Núñez C, Grijalva I, Escalante-Santiago D and Orozco-Suarez S: Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacol Rep. 69:504–511. 2017. View Article : Google Scholar | |
Lv Y, Wang Z, Liu C and Cui L: Identification of a novel CACNA1A mutation in a Chinese family with autosomal recessive progressive myoclonic epilepsy. Neuropsychiatr Dis Treat. 13:2631–2636. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kozera-Kępniak A, Jastrzębski K, Walenczak J, Klimek A and Głąbiński A: 66034T/C polymorphism of the human pregnane X receptor (hPXR) as potential risk factor for drug resistance in epilepsy-Preliminary study. Neurol Neurochir Pol. 51:19–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Gao H, Bao X, Zhang Q, Li J, Wei L, Wu X, Chen Y and Yu S: SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures. BMC Med Genet. 18:1042017. View Article : Google Scholar : PubMed/NCBI | |
Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D, Chiti L, Rutigliano D, Bianchini C, Virdo S, et al: Diagnostic targeted resequencing in 349 patients with drug-resistant pediatric epilepsies identifies causative mutations in 30 different genes. Hum Mutat. 38:216–225. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kimizu T, Takahashi Y, Oboshi T, Horino A, Koike T, Yoshitomi S, Mori T, Yamaguchi T, Ikeda H, Okamoto N, et al: A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy. Brain Dev. 39:256–260. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shen D, Hernandez CC, Shen W, Hu N, Poduri A, Shiedley B, Rotenberg A, Datta AN, Leiz S, Patzer S, et al: De novo GABRG2 mutations associated with epileptic encephalopathies. Brain. 140:49–67. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q, Li J, Zhao Y, Bao X, Wei L and Wang J: Gene mutation analysis of 175 Chinese patients with early-onset epileptic encephalopathy. Clin Genet. 91:717–724. 2017. View Article : Google Scholar : PubMed/NCBI | |
Miao P, Peng J, Chen C, Gai N and Yin F: A novel mutation in KCNB1 gene in a child with neuropsychiatric comorbidities with both intellectual disability and epilepsy and review of literature. Zhonghua Er Ke Za Zhi. 55:115–119. 2017.(In Chinese). PubMed/NCBI | |
Perucca P, Scheffer IE, Harvey AS, James PA, Lunke S, Thorne N, Gaff C, Regan BM, Damiano JA, Hildebrand MS, et al: Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy. Epilepsy Res. 131:1–8. 2017. View Article : Google Scholar : PubMed/NCBI | |
Guo M, Wang J, Qi H, Liu F, Yao L, Zhang S and Li K: Polymorphisms in the receptor for advanced glycation end products gene are associated with susceptibility to drug-resistant epilepsy. Neurosci Lett. 619:137–141. 2016. View Article : Google Scholar : PubMed/NCBI | |
Stasiołek M, Romanowicz H, Połatyńska K, Chamielec M, Skalski D, Makowska M and Smolarz B: Association between C3435T polymorphism of MDR1 gene and the incidence of drug-resistant epilepsy in the population of Polish children. Behav Brain Funct. 12:212016. View Article : Google Scholar : PubMed/NCBI | |
Abo El Fotoh WM, Abd El Naby SA, Habib MS, ALrefai AA and Kasemy ZA: The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children. Seizure. 41:75–80. 2016. View Article : Google Scholar : PubMed/NCBI | |
Xue T and Lu ZN: Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population. Genet Mol Res. 15:2016. View Article : Google Scholar : | |
Moen MN, Fjaer R, Hamdani EH, Laerdahl JK, Menchini RJ, Vigeland MD, Sheng Y, Undlien DE, Hassel B, Salih MA, et al: Pathogenic variants in KCTD7 perturb neuronal K+ fluxes and glutamine transport. Brain. 139:3109–3120. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hildebrand MS, Griffin NG, Damiano JA, Cops EJ, Burgess R, Ozturk E, Jones NC, Leventer RJ, Freeman JL, Harvey AS, et al: Mutations of the sonic hedgehog pathway underlie hypothalamic hamartoma with gelastic epilepsy. Am J Hum Genet. 99:423–429. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hardies K, Cai Y, Jardel C, Jansen AC, Cao M, May P, Djémié T, Hachon Le Camus C, Keymolen K, Deconinck T, et al: Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline. Brain. 139:2420–2430. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lionel AC, Monfared N, Scherer SW, Marshall CR and Mercimek-Mahmutoglu S: MED23-associated refractory epilepsy successfully treated with the ketogenic diet. Am J Med Genet A. 170:2421–2425. 2016. View Article : Google Scholar : PubMed/NCBI | |
Balestrini S, Milh M, Castiglioni C, Lüthy K, Finelli MJ, Verstreken P, Cardon A, Stražišar BG, Holder JL Jr, Lesca G, et al: TBC1D24 genotype-phenotype correlation: Epilepsies and other neurologic features. Neurology. 87:77–85. 2016. View Article : Google Scholar : PubMed/NCBI | |
Fahrner JA, Liu R, Perry MS, Klein J and Chan DC: A novel de novo dominant negative mutation in DNM1L impairs mitochondrial fission and presents as childhood epileptic encephalopathy. Am J Med Genet A. 170:2002–2011. 2016. View Article : Google Scholar : PubMed/NCBI | |
Vanstone JR, Smith AM, McBride S, Naas T, Holcik M, Antoun G, Harper ME, Michaud J, Sell E, Chakraborty P, et al: DNM1L-related mitochondrial fission defect presenting as refractory epilepsy. Eur J Hum Genet. 24:1084–1088. 2016. View Article : Google Scholar : PubMed/NCBI | |
Janssen W, Quaegebeur A, Van Goethem G, Ann L, Smets K, Vandenberghe R and Van Paesschen W: The spectrum of epilepsy caused by POLG mutations. Acta Neurol Belg. 116:17–25. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, Kosobucki GJ, Chen W, Schulien AJ, Chiavacci R, et al: GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 99:802–816. 2016. View Article : Google Scholar : PubMed/NCBI | |
Segal E, Pedro H, Valdez-Gonzalez K, Parisotto S, Gliksman F, Thompson S, Sabri J and Fertig E: Diagnostic yield of epilepsy panels in children with medication-refractory epilepsy. Pediatr Neurol. 64:66–71. 2016. View Article : Google Scholar : PubMed/NCBI | |
Palmer S, Towne MC, Pearl PL, Pelletier RC, Genetti CA, Shi J, Beggs AH, Agrawal PB and Brownstein CA: SLC6A1 mutation and ketogenic diet in epilepsy with myoclonic-atonic seizures. Pediatr Neurol. 64:77–79. 2016. View Article : Google Scholar : PubMed/NCBI | |
Inui T, Kobayashi S, Ashikari Y, Sato R, Endo W, Uematsu M, Oba H, Saitsu H, Matsumoto N, Kure S and Haginoya K: Two cases of early-onset myoclonic seizures with continuous parietal delta activity caused by EEF1A2 mutations. Brain Dev. 38:520–524. 2016. View Article : Google Scholar : PubMed/NCBI | |
Horta WG, Paradela E, Figueiredo A, Meira ID, Pereira VC, Rego CC, Oliveira R, Andraus ME, de Lacerda GC, Moura P, et al: Genetic association study of the HLA class II alleles DRB1, DQA1, and DQB1 in patients with pharmacoresistant temporal lobe epilepsy associated with mesial hippocampal sclerosis. Seizure. 31:7–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
Damiano JA, Afawi Z, Bahlo M, Mauermann M, Misk A, Arsov T, Oliver KL, Dahl HH, Shearer AE, Smith RJ, et al: Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia. Hum Mol Genet. 24:4483–4490. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bene J, Hadzsiev K, Komlósi K, Kövesdi E, Mátyás P and Melegh B: De novo SCN1A gene deletion in therapy-resistant Dravet syndrome. Orv Hetil. 156:2009–2012. 2015.(In Hungarian). View Article : Google Scholar : PubMed/NCBI | |
Berghuis B, de Kovel CG, van Iterson L, Lamberts RJ, Sander JW, Lindhout D and Koeleman BP: Complex SCN8A DNA-abnormalities in an individual with therapy resistant absence epilepsy. Epilepsy Res. 115:141–144. 2015. View Article : Google Scholar : PubMed/NCBI | |
Damaj L, Lupien-Meilleur A, Lortie A, Riou É, Ospina LH, Gagnon L, Vanasse C and Rossignol E: CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms. Eur J Hum Genet. 23:1505–1512. 2015. View Article : Google Scholar : PubMed/NCBI | |
Guo Y, Yan KP, Qu Q, Qu J, Chen ZG, Song T, Luo XY, Sun ZY, Bi CL and Liu JF: Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies. PLoS One. 10:e01248962015. View Article : Google Scholar : PubMed/NCBI | |
Liu Z, Yin X, Liu L, Tao H, Zhou H, Ma G, Cui L, Li Y, Zhang S, Xu Z, et al: Association of KEAP1 and NFE2L2 polymorphisms with temporal lobe epilepsy and drug resistant epilepsy. Gene. 571:231–236. 2015. View Article : Google Scholar : PubMed/NCBI | |
Emich-Widera E, Likus W, Kazek B, Sieron AL and Urbanek K: Polymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance-preliminary results. Med Sci Monit. 20:1654–1661. 2014. View Article : Google Scholar : PubMed/NCBI | |
Venkateswaran S, Myers KA, Smith AC, Beaulieu CL, Schwartzentruber JA; FORGE Canada Consortium, ; Majewski J, Bulman D, Boycott KM and Dyment DA: Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation. Epilepsia. 55:e75–e79. 2014. View Article : Google Scholar : PubMed/NCBI | |
Picard F, Makrythanasis P, Navarro V, Ishida S, de Bellescize J, Ville D, Weckhuysen S, Fosselle E, Suls A, De Jonghe P, et al: DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 82:2101–2106. 2014. View Article : Google Scholar : PubMed/NCBI | |
Martin HC, Kim GE, Pagnamenta AT, Murakami Y, Carvill GL, Meyer E, Copley RR, Rimmer A, Barcia G, Fleming MR, et al: Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet. 23:3200–3211. 2014. View Article : Google Scholar : PubMed/NCBI | |
Seven M, Batar B, Unal S, Yesil G, Yuksel A and Guven M: The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. Mol Biol Rep. 41:331–336. 2014. View Article : Google Scholar : PubMed/NCBI | |
Escalante-Santiago D, Feria-Romero IA, Ribas-Aparicio RM, Rayo-Mares D, Fagiolino P, Vázquez M, Escamilla-Núñez C, Grijalva-Otero I, López-Garcia MA and Orozco-Suárez S: MDR-1 and MRP2 gene polymorphisms in mexican epileptic pediatric patients with complex partial seizures. Front Neurol. 5:1842014. View Article : Google Scholar : PubMed/NCBI | |
Seven M, Batar B, Unal S, Yesil G, Yuksel A and Guven M: The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children. Mol Diagn Ther. 18:229–236. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z and Zhong MK: Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 15:1323–1336. 2014. View Article : Google Scholar : PubMed/NCBI | |
He X, Li Y, Liu Z, Yue X, Zhao P, Hu J, Wu G, Mao B, Sun D, Zhang H, et al: The association between CCL2 polymorphisms and drug-resistant epilepsy in Chinese children. Epileptic Disord. 15:272–277. 2013. View Article : Google Scholar : PubMed/NCBI | |
Serino D, Specchio N, Pontrelli G, Vigevano F and Fusco L: Video/EEG findings in a KCNQ2 epileptic encephalopathy: A case report and revision of literature data. Epileptic Disord. 15:158–165. 2013.PubMed/NCBI | |
Emich-Widera E, Likus W, Kazek B, Niemiec P, Balcerzyk A, Sieroń AL and Zak I: CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013:5268372013. View Article : Google Scholar : PubMed/NCBI | |
Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-Maron A, Greenberg ME, Stuhlmann T, Weinert S, et al: Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 54:1270–1281. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fragaki K, Ait-El-Mkadem S, Chaussenot A, Gire C, Mengual R, Bonesso L, Beneteau M, Ricci JE, Desquiret-Dumas V, Procaccio V, et al: Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur J Hum Genet. 21:528–534. 2013. View Article : Google Scholar : PubMed/NCBI | |
Subenthiran S, Abdullah NR, Joseph JP, Muniandy PK, Mok BT, Kee CC, Ismail Z and Mohamed Z: Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. PLoS One. 8:e648272013. View Article : Google Scholar : PubMed/NCBI | |
Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, Tang Q, Zhou HH and Liu ZQ: ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther. 18:647–651. 2012. View Article : Google Scholar : PubMed/NCBI | |
Dimova PS, Kirov A, Todorova A, Todorov T and Mitev V: A novel PCDH19 mutation inherited from an unaffected mother. Pediatr Neurol. 46:397–400. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sayyah M, Kamgarpour F, Maleki M, Karimipoor M, Gharagozli K and Shamshiri AR: Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients. Epileptic Disord. 13:155–165. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lakhan R, Kumari R, Singh K, Kalita J, Misra UK and Mittal B: Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. Indian J Med Res. 134:295–301. 2011.PubMed/NCBI | |
Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK and Mittal B: Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 17 (Suppl 1):S32–S40. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Wong KS and Baum L: Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 12:319–325. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kim DU, Kim MK, Cho YW, Kim YS, Kim WJ, Lee MG, Kim SE, Nam TS, Cho KH, Kim YO and Lee MC: Association of a synonymous GAT3 polymorphism with antiepileptic drug pharmacoresistance. J Hum Genet. 56:640–646. 2011. View Article : Google Scholar : PubMed/NCBI | |
Meng H, Guo G, Ren J, Zhou H, Ge Y and Guo Y: Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 21:27–30. 2011. View Article : Google Scholar : PubMed/NCBI | |
Alpman A, Ozkinay F, Tekgul H, Gokben S, Pehlivan S, Schalling M and Ozkinay C: Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy. J Child Neurol. 25:1485–1490. 2010. View Article : Google Scholar : PubMed/NCBI | |
Maleki M, Sayyah M, Kamgarpour F, Karimipoor M, Arab A, Rajabi A, Gharagozli K, Shamshiri AR and Shahsavand Ananloo E: Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients. Iran Biomed J. 14:89–96. 2010.PubMed/NCBI | |
Di Bonaventura C, Carni M, Diani E, Fattouch J, Vaudano EA, Egeo G, Pantano P, Maraviglia B, Bozzao L, Manfredi M, et al: Drug resistant ADLTE and recurrent partial status epilepticus with dysphasic features in a family with a novel LGI1mutation: Electroclinical, genetic, and EEG/fMRI findings. Epilepsia. 50:2481–2486. 2009. View Article : Google Scholar : PubMed/NCBI | |
Jang SY, Kim MK, Lee KR, Park MS, Kim BC, Cho KH, Lee MC and Kim YS: Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J Korean Med Sci. 24:62–68. 2009. View Article : Google Scholar : PubMed/NCBI | |
Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, Nayak G, Bhaskaranand N, Banerjee M and Satyamoorthy K: Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet. 24:255–260. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Poon WS, Ng HK, Wong KS and Baum L: Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 10:723–732. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kauffman MA, Consalvo D, Gonzalez-Morón D, Aguirre F, D'Alessio L and Kochen S: Serotonin transporter gene variation and refractory mesial temporal epilepsy with hippocampal sclerosis. Epilepsy Res. 85:231–234. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S and Mittal B: Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol. 68:214–220. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, Cances C, Ville D, Afenjar A, Rio M, et al: Key clinical features to identify girls with CDKL5 mutations. Brain. 131:2647–2661. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS and Baum L: Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: Correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genom. 18:989–998. 2008. View Article : Google Scholar | |
Elia M, Falco M, Ferri R, Spalletta A, Bottitta M, Calabrese G, Carotenuto M, Musumeci SA, Lo Giudice M and Fichera M: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 71:997–999. 2008. View Article : Google Scholar : PubMed/NCBI | |
Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M and Nakagawa K: Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 66:304–307. 2008. View Article : Google Scholar : PubMed/NCBI | |
Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, McCarthy M, Kinirons P, Goldstein D and Delanty N: The controversial association of ABCB1 polymorphisms in refractory epilepsy: An analysis of multiple SNPs in an Irish population. Epilepsy Res. 73:192–198. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, Hui AC, Yu E and Wong LK: Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 11:112–117. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hung CC, Jen Tai J, Kao PJ, Lin MS and Liou HH: Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics. 8:1151–1158. 2007. View Article : Google Scholar : PubMed/NCBI | |
Leschziner GD, Jorgensen AL, Andrew T, Williamson PR, Marson AG, Coffey AJ, Middleditch C, Balding DJ, Rogers J, Bentley DR, et al: The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics. 8:1715–1722. 2007. View Article : Google Scholar : PubMed/NCBI | |
Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K and Nakagawa K: ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 7:551–561. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hung CC, Tai JJ, Lin CJ, Lee MJ and Liou HH: Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 6:411–417. 2005. View Article : Google Scholar : PubMed/NCBI | |
Mills PB, Surtees RA, Champion MP, Beesley CE, Dalton N, Scambler PJ, Heales SJ, Briddon A, Scheimberg I, Hoffmann GF, et al: Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet. 14:1077–1086. 2005. View Article : Google Scholar : PubMed/NCBI | |
Buono RJ, Lohoff FW, Sander T, Sperling MR, O'Connor MJ, Dlugos DJ, Ryan SG, Golden GT, Zhao H, Scattergood TM, et al: Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility. Epilepsy Res. 58:175–183. 2004. View Article : Google Scholar : PubMed/NCBI | |
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW and Sisodiya SM: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 348:1442–1448. 2003. View Article : Google Scholar : PubMed/NCBI | |
Gambardella A, Manna I, Labate A, Chifari R, La Russa A, Serra P, Cittadella R, Bonavita S, Andreoli V, LePiane E, et al: GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology. 60:560–563. 2003. View Article : Google Scholar : PubMed/NCBI |